HTBA announced today the entry of Miura Partners as the majority shareholder of the company, a move aligned with its significant growth plans for the coming years. The new owner has reached an agreement with Riverside, which will exit the shareholder structure after five years during which HTBA has focused on its international expansion and modernization of its facilities in Spain and the United States.
The agreement with Miura Partners signifies the consolidation of HTBA’s operations, which are based on four business areas: Functional Health, Pharmaceutical Active Ingredients (APIs), Taste Modulation, and Animal Nutrition.
“This new chapter in the company’s history represents a significant progress and the consolidation of our growth strategy based on innovation and sustainability. We remain focused on providing solutions that enhance the health and well-being of both people and animals, as a global leader in the manufacturing and distribution of flavonoids and active forms of vitamin B12,” explained Alexandre Valls-Coma, Chief Executive Officer of HTBA.
“We are very pleased with our investment in HTBA, a leader in the strategic natural ingredients sector for the pharmaceutical and nutrition industries, with a strong track record in innovation, growth and sustainability. This investment aligns well with our mid-market buy-outs strategy, focusing on industry-leading companies with solid business models, strong growth potential and a top-tier management team”, explained Jordi Alegre, Managing Partner at Miura Partners.
As an international company, HTBA has achieved a revenue of 80 million euros, is composed by a team of over 200 people, and exports its products to more than 60 countries worldwide. Headquartered in Barcelona, with a subsidiary in Cincinnati, Ohio, it also operates a research, development, and production center in Beniel (Murcia).
Due to its commitment to innovation and sustainable industrial development, HTBA’s recent years have been marked by growth, doubling both its revenue and workforce. Since 2019, revenue has increased from 48 million euros to 80 million euros, while over 100 individuals have joined its current workforce of 200 employees in recent years.
About HTBA
With nearly 50 years of history, HTBA is currently a global leader in the manufacturing and distribution of flavonoids and active forms of vitamin B12. The company is at the forefront of research, development, and production of high-value-added ingredients, harnessing the power of nature while ensuring sustainability for future generations.
About Miura Partners
Miura Partners is a purpose-driven Private Equity firm. With offices in Barcelona and Madrid, the firm specializes in investing in small and medium-sized family- owned and entrepreneurial companies. Miura provides attractive growth and innovation plans with a clear focus on sustainability and internationalization. The firm currently manages assets exceeding €1.5bn and has completed more than 70 investments worth more than €3.0bn since its inception in 2008.
